Community Based Prevention of Rotavirus Gastroenteritis by a Functional Food Supplement

February 3, 2015 updated by: Christian Medical College, Vellore, India

Community Based Prophylaxis for Rotavirus Gastroenteritis in Children by an Anti-rotavirus Protein Based Food Supplement

Rotavirus is the commonest cause of severe gastroenteritis in young children worldwide. The investigators hypothesize that use of a food based prophylactic will decrease incidence of rotavirus infection in young children in south India, prevent intestinal damage and overall result in lower infection rates and better gut function. This trial will evaluate the efficacy of prevention of rotavirus gastroenteritis when an anti-rotavirus protein or antibody fragments expressed in yeast or placebo are given daily as a food supplement to children between the ages of 6 and 12 months. The children will followed for one year and rates of rotavirus diarrhoea, antibody responses and gut function will be compared between children receiving antibody fragments or placebo.

Study Overview

Detailed Description

The study will be carried out in an urban slum area in Vellore, south India. Children between the ages of 6 and 12 months will be recruited for participation in the study. They will be randomized to receive supplementation with ARP or placebo, and will be followed for a period of one year, with weekly home visits and monitoring of all episodes of diarrhoea. In addition, every two weeks, surveillance stool samples will be collected and tested for rotavirus to identify asymptomatic infections by PCR. All episodes of diarrhoea will be investigated intensively for bacterial, viral and parasitic agents of diarrhoea using both conventional and molecular techniques and all cases will be treated appropriately at the study clinic or referral hospital as required. Monthly anthropometric measurements will be carried out to estimate rates of growth and to identify growth faltering. Blood samples will be taken at 4, 8 and 12 months for estimation of anti-rotavirus IgA and IgG antibodies. Studies on intestinal absorption and permeability will be carried out at recruitment, 6 and 12 months by the lactulose:mannitol test (measured by HPLC detection of sugars). All rotavirus strains obtained will be characterized by genotyping.

Study Type

Interventional

Enrollment (Actual)

330

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • TN
      • Vellore, TN, India, 632004
        • Christian Medical College

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 months to 1 year (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Healthy child aged 6 to 12 months, families resident in the study area, willing to participate and available for follow up for a period of one year
  • Normal birth weight (> 2.5 kg), child exclusively breast fed for at least four months

Exclusion Criteria:

  • Families not available for a follow up period of one year
  • Children with any atopic conditions
  • Children with gross congenital anomalies including cardiovascular, renal or hepatic disease
  • Children with syndromic or serological evidence of HIV infection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Maltodextrin
Maltodextrin 1 gm daily
Experimental: Anti-rotavirus protein
11mg ARP In 1 Gm Product Daily For 12 Months, given in orange juice

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Incidence of rotavirus gastroenteritis
Time Frame: One year after recruitment
One year after recruitment

Secondary Outcome Measures

Outcome Measure
Time Frame
IgA And IgG Antibody Response To Rotavirus
Time Frame: At 4, 8 And 12 Months after recruitment
At 4, 8 And 12 Months after recruitment
Weight For Height Z Score
Time Frame: At 6 and 12 months after recruitment
At 6 and 12 months after recruitment
Intestinal Function by lactulose:mannitol
Time Frame: at 3, 6, 9 and 12 months
at 3, 6, 9 and 12 months
Characterization of strains causing rotavirus gastroenteritis
Time Frame: Over 12 months
Over 12 months
Incidence of adverse events
Time Frame: Over 12 months
Over 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Gagandeep Kang, MD, Christian Medical College, Vellore, India
  • Study Director: Uma Raman, MDS, Christian Medical College, Vellore, India

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2011

Primary Completion (Actual)

June 1, 2012

Study Completion (Actual)

June 1, 2012

Study Registration Dates

First Submitted

December 21, 2010

First Submitted That Met QC Criteria

December 22, 2010

First Posted (Estimate)

December 23, 2010

Study Record Updates

Last Update Posted (Estimate)

February 4, 2015

Last Update Submitted That Met QC Criteria

February 3, 2015

Last Verified

February 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • CMCLB001

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rotavirus Gastroenteritis

Clinical Trials on Anti-rotavirus protein

3
Subscribe